Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $154.74 billion. The enterprise value is $206.13 billion.
| Market Cap | 154.74B |
| Enterprise Value | 206.13B |
Important Dates
The last earnings date was Wednesday, October 30, 2024, after market close.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | Nov 18, 2024 |
Share Statistics
Amgen has 537.53 million shares outstanding. The number of shares has increased by 0.42% in one year.
| Current Share Class | 537.53M |
| Shares Outstanding | 537.53M |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 79.31% |
| Float | 536.06M |
Valuation Ratios
The trailing PE ratio is 36.75 and the forward PE ratio is 13.96. Amgen's PEG ratio is 2.74.
| PE Ratio | 36.75 |
| Forward PE | 13.96 |
| PS Ratio | 4.75 |
| Forward PS | 4.52 |
| PB Ratio | 20.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.63 |
| P/OCF Ratio | 21.32 |
| PEG Ratio | 2.74 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.83, with an EV/FCF ratio of 32.81.
| EV / Earnings | 48.73 |
| EV / Sales | 6.34 |
| EV / EBITDA | 16.83 |
| EV / EBIT | 30.89 |
| EV / FCF | 32.81 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 8.02.
| Current Ratio | 1.32 |
| Quick Ratio | 0.80 |
| Debt / Equity | 8.02 |
| Debt / EBITDA | 4.86 |
| Debt / FCF | 9.61 |
| Interest Coverage | 2.07 |
Financial Efficiency
Return on equity (ROE) is 55.72% and return on invested capital (ROIC) is 6.13%.
| Return on Equity (ROE) | 55.72% |
| Return on Assets (ROA) | 4.60% |
| Return on Capital (ROIC) | 6.13% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | $158,427 |
| Employee Count | 26,700 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Amgen has paid $449.00 million in taxes.
| Income Tax | 449.00M |
| Effective Tax Rate | 9.60% |
Stock Price Statistics
The stock price has increased by +8.47% in the last 52 weeks. The beta is 0.60, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +8.47% |
| 50-Day Moving Average | 318.08 |
| 200-Day Moving Average | 305.92 |
| Relative Strength Index (RSI) | 33.17 |
| Average Volume (20 Days) | 2,785,227 |
Short Selling Information
The latest short interest is 8.82 million, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 8.82M |
| Short Previous Month | 9.37M |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 5.11 |
Income Statement
In the last 12 months, Amgen had revenue of $32.53 billion and earned $4.23 billion in profits. Earnings per share was $7.83.
| Revenue | 32.53B |
| Gross Profit | 19.71B |
| Operating Income | 6.67B |
| Pretax Income | 3.53B |
| Net Income | 4.23B |
| EBITDA | 12.25B |
| EBIT | 6.67B |
| Earnings Per Share (EPS) | $7.83 |
Balance Sheet
The company has $9.01 billion in cash and $60.40 billion in debt, giving a net cash position of -$51.39 billion or -$95.60 per share.
| Cash & Cash Equivalents | 9.01B |
| Total Debt | 60.40B |
| Net Cash | -51.39B |
| Net Cash Per Share | -$95.60 |
| Equity (Book Value) | 7.53B |
| Book Value Per Share | 14.00 |
| Working Capital | 6.45B |
Cash Flow
In the last 12 months, operating cash flow was $7.26 billion and capital expenditures -$974.00 million, giving a free cash flow of $6.28 billion.
| Operating Cash Flow | 7.26B |
| Capital Expenditures | -974.00M |
| Free Cash Flow | 6.28B |
| FCF Per Share | $11.69 |
Margins
Gross margin is 60.59%, with operating and profit margins of 20.51% and 13.00%.
| Gross Margin | 60.59% |
| Operating Margin | 20.51% |
| Pretax Margin | 14.38% |
| Profit Margin | 13.00% |
| EBITDA Margin | 37.64% |
| EBIT Margin | 20.51% |
| FCF Margin | 17.72% |
Dividends & Yields
This stock pays an annual dividend of $9.00, which amounts to a dividend yield of 3.13%.
| Dividend Per Share | $9.00 |
| Dividend Yield | 3.13% |
| Dividend Growth (YoY) | 5.63% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 114.90% |
| Buyback Yield | -0.42% |
| Shareholder Yield | 2.71% |
| Earnings Yield | 2.73% |
| FCF Yield | 4.06% |
Analyst Forecast
The average price target for Amgen is $334.58, which is 16.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $334.58 |
| Price Target Difference | 16.23% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 5.00% |
| EPS Growth Forecast (5Y) | 12.43% |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.44 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 6 |